News Release

A pill to strengthen muscle and bone

Peer-Reviewed Publication

Tokyo Medical and Dental University

LAMZ augments muscle and bone by mimicking calcium signaling to induce PGC-1α

image: Exercise induces calcium signaling in the muscle and bone. Under this signaling, PGC-1α is activated, resulting in the augmentation of these tissues. LAMZ, a newly identified locomomimetic drug was found to facilitate the calcium signaling pathway and restores locomotor fitness. view more 

Credit: Department of Cell Signaling, TMDU

Researchers led by Tokyo Medical and Dental University (TMDU) identify a drug that mimics the effects of exercise on muscle and bone in mice  


Tokyo, Japan – Maintaining a regular workout routine can help you look and feel great – but did you know that exercise also helps maintain your muscles and bones? People who are unable to engage in physical activity experience weakening of the muscles and bones, a condition known as locomotor frailty. Recently, researchers in Japan have identified a new drug that may aid in the treatment of locomotor frailty by inducing similar effects as exercise.


Physical inactivity can result in a weakening of the muscles (known as sarcopenia) and bones (known as osteoporosis). Exercise dispels this frailty, increasing muscle strength and promoting bone formation while suppressing bone resorption. However, exercise therapy cannot be applied to all clinical cases. Drug therapy may be helpful in treating sarcopenia and osteoporosis, especially when patients have cerebrovascular disease, dementia, or when they have already become bedridden. However, there is no single drug that addresses both tissues simultaneously.


In a new study published in Bone Research, researchers from Tokyo Medical and Dental University (TMDU) developed a novel drug screening system to identify a compound that mimics the changes in muscle and bone that occur as a result of exercise. Using the screening system, the researchers identified the aminoindazole derivative locamidazole (LAMZ). LAMZ was capable of stimulating the growth of muscle cells and bone-forming cells, osteoblasts, while suppressing the growth of bone-resorbing cells, osteoclasts.


When LAMZ was administrated to mice orally, it was successfully transmitted into the blood, with no obvious side effects. “We were pleased to find that LAMZ-treated mice exhibited larger muscle fiber width, greater maximal muscle strength, a higher rate of bone formation, and lower bone resorption activity,” says lead author of the study Takehito Ono.


The research team further addressed the mode of function of LAMZ and found that LAMZ mimics calcium and PGC-1α signaling pathways. These pathways are activated during exercise and stimulate expression of downstream molecules that are involved in the maintenance of muscle and bone.


To investigate whether LAMZ can treat locomotor frailty, LAMZ was administrated to an animal model of sarcopenia and osteoporosis. “Both oral and subcutaneous administration of the drug improved the muscle and bone of mice with locomotor frailty,” says senior author Tomoki Nakashima.


Taken together, the research team’s findings show that LAMZ represents a potential therapeutic method for the treatment of locomotor frailty by mimicking exercise.




The article, “Simultaneous augmentation of muscle and bone by locomomimetism through

calcium–PGC-1α signaling,” was published in Bone Research at DOI: 10.1038/s41413-022-00225-w.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.